Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF EIF4E-BP2 EXPRESSION
    Publication number: 20090203765
    Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.
    Type: Application
    Filed: November 21, 2006
    Publication date: August 13, 2009
    Applicant: ISIS PHARMACEUTICALS, INC
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Ravi Jain
  • Modulation of Tudor-SN expression
    Patent number: 7563885
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: July 21, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Ming-Yi Chiang, Kenneth W. Dobie
  • COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION
    Publication number: 20090156526
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Application
    Filed: October 17, 2006
    Publication date: June 18, 2009
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke
  • MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
    Publication number: 20090156538
    Abstract: Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.
    Type: Application
    Filed: October 30, 2008
    Publication date: June 18, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Kenneth W. Dobie
  • ANTISENSE MODULATION OF PTP1B EXPRESSION
    Publication number: 20090124009
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: March 11, 2008
    Publication date: May 14, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • MODULATION OF EIF4E-BP2 EXPRESSION
    Publication number: 20090082302
    Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.
    Type: Application
    Filed: November 19, 2008
    Publication date: March 26, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Ravi Jain
  • Modulation of endothelial lipase expression
    Patent number: 7507808
    Abstract: Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: March 24, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Kenneth W. Dobie
  • Topical administrations of antisense compounds to vla-4 for the treatment of respiratory conditions
    Publication number: 20090029931
    Abstract: A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin ?4 comprising administering to the animal a composition comprising from. 0.001 to 1000 ?g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin ?4.
    Type: Application
    Filed: October 20, 2005
    Publication date: January 29, 2009
    Inventors: George Tachas, James C. Karras, Susan Gregory, Jeffrey R. Crosby, Kenneth W. Dobie, C. Frank Bennett
  • Modulation of eIF4E-BP2 expression
    Patent number: 7468431
    Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: December 23, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Ravi Jain
  • Modulation of insulin like growth factor I receptor expression
    Patent number: 7468356
    Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: December 23, 2008
    Assignee: Antisense Therapeutics Ltd.
    Inventors: Cristopher John Wraight, George Arthur Werther, Nicholas M. Dean, Kenneth W. Dobie
  • Compositions and Their Uses Directed to Ptpru
    Publication number: 20080280845
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.
    Type: Application
    Filed: May 24, 2006
    Publication date: November 13, 2008
    Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
  • Antisense Modulation of P38 Mitogen Activated Protein Kinase Expression
    Publication number: 20080194503
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.
    Type: Application
    Filed: August 12, 2004
    Publication date: August 14, 2008
    Inventors: Brett P. Monia, Kenneth W. Dobie, Susan M. Freier, Ian Popoff, Wai Shiu Fred Wong, James G. Karras
  • Modulation of glucagon receptor expression
    Patent number: 7399853
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: July 15, 2008
    Assignee: ISIS Pharmaceuticals
    Inventors: Susan M. Freier, Kenneth W. Dobie, Sanjay Bhanot, Robert McKay
  • MODULATION OF FORKHEAD BOX O1A EXPRESSION
    Publication number: 20080153767
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Application
    Filed: April 23, 2007
    Publication date: June 26, 2008
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
  • Antisense modulation of stearoyl-CoA desaturase expression
    Publication number: 20080153766
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 26, 2008
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, John G. Geisler, Mark J. Graham
  • Modulation of Aurora B expression
    Patent number: 7375212
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B are provided. Also provided are methods of using these compounds to modulate the growth of cancer cells, including p53-deficient cancer cells.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: May 20, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Kenneth W. Dobie, Erich Koller
  • Modulation of forkhead box O1A expression
    Patent number: 7229976
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: June 12, 2007
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter
  • Modulation of HIF1? and HIF2? expression
    Patent number: 7217572
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: May 15, 2007
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier
  • Antisense modulation of kinesin-like 1 expression
    Patent number: 7199107
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: April 3, 2007
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Erich Koller
  • Antisense modulation of kinesin-like 1 expression
    Patent number: 7163927
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: January 16, 2007
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Erich Koller